The following is a sample from a larger document.
This section is for: Regulatory and Agency History
The section is from a Focused Issue Brief on: Assessing Scientific Causation Claims in PFAS Exposure Litigation
The primary research jurisdiction is: United States of America
[Back]
Regulatory and Agency History
The Environmental Protection Agency has approached per- and polyfluoroalkyl substances (PFAS) through a patchwork of regulatory responses spanning four decades, with the agency’s position evolving from minimal oversight to increasingly aggressive regulation. This regulatory history reveals significant gaps, reversals, and internal contradictions that bear directly on the strength of causation claims in PFAS litigation.
Early Recognition and Initial Inaction (1980s-2000s)
EPA’s earliest documented awareness of PFAS compounds dates to the 1980s, when the agency classified perfluorooctanoic acid (PFOA) under the Toxic Substances Control Act (TSCA) as an unregulated chemical substance. Publicly released EPA documents from this period reflect agency scientists noting concerns about the persistence and bioaccumulation potential of these compounds. No regulatory action followed.
The agency’s 1998 response to a 3M company submission regarding PFOS environmental fate studies illustrates this early pattern. EPA acknowledged that PFOS “does not readily biodegrade” and noted its presence in wildlife samples, but concluded that existing data were insufficient to support regulatory restrictions. The agency requested additional studies from 3M but set no deadlines and established no interim protective measures.
When DuPont notified EPA in 2004 of elevated PFOA levels in drinking water near its West Virginia facility, the agency’s response focused on gathering additional information rather than immediate protective action. DuPont had possessed this data since 2000. EPA’s enforcement response consisted of a consent agreement requiring DuPont to fund further health studies, with no admission of violation and no immediate restrictions on PFOA use.
The 2006 PFOA Stewardship Program
EPA’s most significant early regulatory response came through the 2006 PFOA Stewardship Program, a voluntary agreement with eight major chemical manufacturers to phase out PFOA production and use by 2015. The program represented a notable departure from traditional command-and-control regulation, relying instead on industry commitments to achieve reductions.
The agency’s rationale for choosing voluntary measures over mandatory regulation, documented in Federal Register notices and internal memoranda, centered on what EPA characterized as “scientific uncertainty” regarding human health effects. Agency documents from this period consistently describe PFOA as presenting “potential risk” rather than established harm.
This characterization later became a point of dispute in litigation, where plaintiffs argued EPA had understated known risks.
The Stewardship Program achieved its stated goal: participating companies eliminated PFOA from production by 2015. However, EPA did not simultaneously restrict the import of PFOA-containing products from non-participating manufacturers, nor did it address the environmental persistence of PFOA already released. The agency acknowledged these limitations in program assessments but did not propose supplementary measures to address them.
Drinking Water Standards Development (2009-2016)
EPA’s approach to PFAS in drinking water reveals perhaps the most significant contradictions in the agency’s regulatory record. The agency’s 2009 decision to include PFOA and PFOS on its Contaminant Candidate List for potential regulation under the Safe Drinking Water Act marked the beginning of a protracted standard-setting process that exposed internal disagreements about appropriate health benchmarks.
Initial draft documents proposed health advisory levels for PFOA of 400 parts per trillion, based on developmental effects studies in laboratory animals. By 2014, EPA scientists were recommending levels below 100 parts per trillion, citing new epidemiological data from the C8 Science Panel studies in West Virginia and Ohio.
EPA’s 2016 establishment of health advisory levels at 70 parts per trillion for PFOA and PFOS combined represented a significant departure from the agency’s earlier risk assessments. Public materials associated with EPA’s advisory development indicate that alternative advisory levels were considered during the internal review process, including separate evaluations for each compound. The final combined advisory level reflected both health-based calculations and broader policy considerations described in agency materials.
While the final advisory treated PFOA and PFOS as additive for health effects purposes, the agency declined to address other PFAS compounds despite acknowledging their widespread presence in drinking water systems. This selective approach created what EPA’s own Science Advisory Board characterized as an “incomplete regulatory framework” that did not address the full scope of PFAS exposure.
TSCA Regulation Under Different Administrations
Under the Obama administration, EPA began requiring manufacturers to report PFAS production volumes and uses through TSCA Section 8(a) reporting rules, establishing a baseline for understanding domestic PFAS commerce.
The Trump administration’s approach represented a notable departure from this trajectory. EPA’s 2018 decision to exempt certain PFAS compounds from new chemical review requirements drew criticism from agency scientists, whose concerns were documented in internal memoranda released through subsequent Freedom of Information Act litigation. These documents reflect internal disagreement about whether certain exemptions aligned with the agency’s risk assessment guidelines and how they might affect the introduction of related PFAS compounds.
The Biden administration reversed several of these exemptions through a 2021 administrative order, but the regulatory treatment had changed course multiple times. Defendants have argued that changing EPA positions demonstrate scientific uncertainty about PFAS risks. Plaintiffs have pointed to the same changes as evidence of industry influence on regulatory decision-making.
Superfund Designation and Enforcement Policy
EPA’s 2022 proposal to designate PFOA and PFOS as hazardous substances under CERCLA represents the agency’s most aggressive regulatory stance to date, but the designation process has exposed significant internal contradictions in EPA’s assessment of PFAS environmental persistence and toxicity.
The proposed rule’s supporting documentation relies on toxicity studies that had been discussed in earlier agency assessments in different regulatory contexts. The agency’s 2016 drinking water advisory development process had questioned the relevance of certain animal studies for human health assessment, yet the same studies became central to EPA’s 2022 CERCLA hazard determination. Agency documents characterize this shift as reflecting updated scientific interpretation.
EPA’s enforcement guidance accompanying the CERCLA proposal suggests agency confidence in linking specific sources to environmental harm through “polluter pays” principles. However, EPA’s own technical guidance acknowledges significant challenges in source attribution for PFAS contamination, particularly in areas with multiple potential sources or long contamination histories.
The agency’s approach to natural resource damage assessments for PFAS contamination has proven particularly inconsistent. EPA’s 2023 guidance documents endorse natural resource damage claims for PFAS-affected ecosystems while simultaneously acknowledging that ecological effects thresholds for most PFAS compounds remain undefined.
Research and Risk Assessment Evolution
EPA’s Office of Research and Development has published risk assessments for PFAS compounds that show substantial evolution in the agency’s understanding of dose-response relationships and exposure pathways. The agency’s 2016 health advisory derivation relied primarily on animal studies and limited human epidemiological data, while its 2022 proposed drinking water standards incorporated extensive human biomonitoring data and community-level health studies.
EPA’s 2016 conclusion that PFOA exposure below 70 parts per trillion was unlikely to cause adverse health effects was replaced by 2022 proposed standards suggesting that any measurable exposure could present health risks. The agency’s technical documents do not fully reconcile these positions, instead characterizing the change as reflecting “advances in scientific understanding.”
EPA’s treatment of cumulative risk from multiple PFAS compounds has remained particularly inconsistent throughout this period. While the agency’s 2016 drinking water advisories treated PFOA and PFOS as additive for certain health endpoints, subsequent risk assessments have not consistently applied cumulative risk approaches to other PFAS compounds, despite acknowledging their widespread co-occurrence in environmental media.
Monitoring and Data Collection Requirements
The agency’s 2012 Unregulated Contaminant Monitoring Rule required large public water systems to test for six PFAS compounds, but the monitoring requirement applied to fewer than 5,000 of the nation’s approximately 50,000 community water systems. The monitoring data collected through this program showed widespread PFAS contamination at levels that exceeded EPA’s subsequently established health advisory levels, yet the agency took no enforcement action against water systems with elevated readings.
EPA’s position, documented in correspondence with state regulators, was that health advisories carry no regulatory force and create no compliance obligations for water utilities.
EPA’s 2020 expansion of PFAS monitoring to include additional compounds and smaller water systems provided more comprehensive contamination data but also revealed the limitations of the agency’s previous oversight. The expanded monitoring showed PFAS contamination in systems that had not been previously tested, including many serving communities near military installations and industrial facilities with known PFAS releases.
EPA has declined to establish a centralized database of PFAS monitoring results, instead requiring individual water systems to report data to state agencies using varying formats and timelines. This decentralized approach has made it difficult to establish comprehensive exposure patterns, particularly for communities served by smaller water systems not subject to federal monitoring requirements.
Military Installation Coordination
EPA’s coordination with the Department of Defense on PFAS contamination at military installations has produced a regulatory record marked by jurisdictional disputes and inconsistent cleanup standards. The agencies’ 2016 memorandum of understanding regarding military PFAS cleanup established EPA health advisory levels as cleanup goals, but DOD has consistently argued for less stringent standards based on its own risk assessments.
EPA’s responses to DOD’s alternative risk assessments, documented in inter-agency correspondence released through congressional oversight, show significant disagreement about appropriate exposure assumptions and acceptable risk levels. Inter-agency correspondence reflects disagreement about exposure modeling assumptions and treatment of sensitive populations, and cleanup standards have varied across installations.
The practical effect has been a patchwork of cleanup standards at military installations, with some sites using EPA health advisory levels while others proceed under DOD’s alternative benchmarks. Defendants have pointed to federal agencies’ disagreement about cleanup levels as evidence of scientific uncertainty about health effects.
State Coordination and Preemption Questions
EPA’s position that state drinking water standards more stringent than federal levels are not preempted by federal law has enabled states to establish PFAS limits well below EPA advisory levels. This has created a regulatory landscape where federal and state health assessments differ substantially, sometimes by more than an order of magnitude.
EPA has provided technical support for state regulatory development, including sharing risk assessment methodologies and exposure data, but has not attempted to harmonize state approaches or establish minimum federal requirements that would override state variations.
The agency’s enforcement coordination with states has proven particularly inconsistent for PFAS contamination cases. EPA has deferred to state cleanup authority in some cases while asserting federal jurisdiction in others, with the choice criteria not clearly established in agency guidance documents. This selective federal involvement has created uncertainty about which regulatory standards apply to specific contamination sites, particularly those involving interstate environmental impacts.
EPA’s regulatory history on PFAS demonstrates an agency grappling with scientific uncertainty while facing mounting evidence of widespread contamination and potential health effects. The agency’s positions have evolved significantly over time, with notable reversals and internal contradictions that bear directly on the strength of regulatory reliance in litigation contexts.
The record reflects an agency that has progressively expanded its regulatory approach to PFAS while operating within statutory authorities and evolving policy considerations.
[Back]